Citations

Clear

367 citation(s) found for "Du, Pan".

Clinical Characteristics and Outcomes of Polyarteritis Nodosa: An International Study
Karadağ, Ömer , Bölek, Ertuğrul Çağrı , Ayan, Gizem , Mohammad, Aladdin J , Grayson, Peter C. , Pagnoux, Christian , Martín‐Nares, Eduardo , Monti, Sara , Abe, Yoshiyuki , Alberici, Federico , Alıbaz-Öner, Fatma , Cuthbertson, David , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Hočevar, Alojzija , Hinojosa‐Azaola, Andrea , Furuta, Shunsuke , Emmi, Giacomo , Özen, Seza , Collaborators, for the GLOBAL‐PAN, Springer, Jason , Simonini, Gabriele , Di̇reskeneli̇, Haner , Khalidi, Nader A , McAlear, Carol A , Warrington, Kenneth J , Hocevar, Alojzija , Hinojosa-Azaola, Andrea , Ozen, Seza , Jayne, David , Merkel, Peter A , Springer, Jason M , Monti, Sara , Pagnoux, Christian , Mohammad, Aladdin J , Dagna, Lorenzo , Khalidi, Nader , Monach, Paul A. , Moroni, Luca , Padoan, Roberto , Seo, Philip , Warrington, Kenneth J. , Jayne, David , Merkel, Peter A. , Collaborators, for the GLOBAL‐PAN

Mayo Clinic

Arthritis & Rheumatology | February 12, 2024 | Volume: 76 | Issue: 7 | Pages: 1120-1129

10.1002/art.42817 | PMID 38343337 Get It

Objective We describe the demographics, clinical features, disease course, and survival of polyarteritis nodosa (PAN) through an international collaboration (GLOBAL‐PAN). Methods Patients with PAN were recruited between 1990 and 2020 from observational cohorts of nine countries across Europe, Japan, and North America. Eligibility was retrospectively defined using the European Medicines Agency classification algorithm. Patients with PAN related to hepatitis B virus (n = 12) and two monogenic diseases mimicking PAN, deficiency of adenosine deaminase 2 enzyme (n = 16) or familial Mediterranean fever (n = 11), were excluded. Data regarding organ involvement, relapse, disease‐related damage, and survival were analyzed. Results Three hundred fifty‐eight patients (female:male ratio 174:184), including those with systemic PAN (sPAN, n = 282) and cutaneous PAN (n = 76), were included. Twenty‐five were pediatric onset. Mean ± SD age at diagnosis was 44.3 ± 18.1 years. Constitutional symptoms (71.5%), cutaneous involvement (70.5%), musculoskeletal findings (69.1%), and neurologic features (48.0%) were common manifestations. Among patients with sPAN, gastrointestinal involvement and proteinuria over 400 mg/day were reported in 52.2% and 11.2%, respectively. During a median (interquartile range) 59.6 (99.5) months of follow‐up, relapse occurred in 48.5% of patients. One, 5‐ and 10‐year survival rates for sPAN were 97.1%, 94.0%, and 89.0%, respectively. Predictors of death for sPAN included age ≥65 years at diagnosis, serum creatinine at diagnosis >140 μmol/L, gastrointestinal manifestations, and central nervous system (CNS) involvement. Conclusion The spectrum of PAN remains a complex, multifaceted disease. Relapse is common. Age ≥65 years and serum creatinine >140 μmol/L at diagnosis, as well as gastrointestinal and CNS involvement, are independent predictors of death in sPAN. image
Efficacy of Mycophenolate Mofetil in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-analysis (5066)
Zhao-Fleming, Hannah , Pan, Jie , Karukote, Amputch , Avila, Mirla , Thakolwiboon, Smathorn

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.5066 Get It

From Nasolabial Folds to Pan-facial Rejuvenation—The Evolution of Fillers in my Career
Grunebaum, Lisa D., Eitan, Dana , Cave, Taylor B.

Mayo Clinic

Facial Plastic Surgery | December 5, 2023 | Volume: 41 | Issue: 01 | Pages: 91-97

10.1055/s-0043-1776995 | PMID 38049110 Get It

AbstractThis is a comprehensive review of facial fillers including landmark studies and expert commentary spanning the years from 2003 (when the first hyaluronic acid [HA] dermal filler underwent Food and Drug Administration approval in United States) to present.
Project Evolve, Evaluation of Lineage Switch (LS), an International Initiative: Preliminary Results Reveal Dismal Outcomes in Patients with LS
Harrison, Cynthia , Biery, D. N. , Zerkalenkova, Elena , Alonso‐Saladrigues, Anna , Utley, Kaylyn, Fernandes, Sneha, Carapia, Naomi Torres, Vatsayan, Anant , Pacenta, Holly , Escherich, Gabriele , Lee, Benjamin J. , Fitzjohn, Mandi R., Larson, Daniel P. , Cuevo, Raymund S., He, Rui , Reed, Kelly, Wölfl, Matthias , Raikar, Sunil S. , Savaşan, Süreyya , Puri, Latika, Gahvari, Zhubin, Talleur, Aimee C. , Abdel‐Azim, Hisham , Chamdin, Aghiad, Provost, Marlie R. M., Mezger, Kerstin, Stevens, Alexandra M. , Hsieh, Emily M. , Duffner, Ulrich, Hoang, Chloe, Davis, Kara L. , Jacoby, Elad , Попов, А. М. , Lamble, Adam J. , Raikar, Sunil S , Zerkalenkova, Elena , Harrison, Cynthia , Lee, Benjamin J , Davis, Kara L , Silbert, Sara K. , Semchenkova, Alexandra , Aldoss, Ibrahim , Zhao, Liping , Rubinstein, Jeremy , Chang, Bill H , De Moerloose, Barbara , Kuo, Dennis J , Redell, Michele S. , Duployez, Nicolas , Dickens, David S. , Chaer, Firas El , Fabrizio, Vanessa A , Wang, Hao‐Wei , Yuan, Constance M. , Pan, Jing , Ghorashian, Sara , Rives, Susana , Shah, Nirali N

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4202-4202

10.1182/blood-2023-182293 Get It

Introduction: Lineage switch (LS) refers to the transformation of acute leukemia from one cell lineage to another (e.g., lymphoid (ALL) to myeloid (AML)). This rare phenomenon, distinct from treatment induced malignancy (i.e., t-AML) and mixed phenotype acute leukemia (MPAL), is increasingly being observed following cell surface antigen targeting. Given challenges in the diagnosis and treatment of LS, Project EVOLVE was developed to globally identify cases of LS following immunotherapy. Methods: A protocol and data collection form for this IRB exempt study was widely disseminated to capture deidentified LS case information across multiple centers and cancer consortia. This included collection of data from published reports of LS, with authors contacted to obtain additional information. For this analysis, LS was defined by the emergence of cell-surface markers warranting reclassification of the original leukemia as a different lineage derivation based on the immunophenotype, including cases of AML emerging alongside the original ALL. “Confirmed” LS cases included those where retention of original cytogenetic or molecular aberrations and/or the clonal immunoglobulin rearrangement patterns were verified to confirm the clonal relationship. “Suspected” LS cases included those where samples to confirm clonality marker retention could not be obtained, but the clinical presentation was consistent with LS. The term “transition” was applied when immunophenotypic shifts were transient. Cases with new cytogenetic abnormalities unrelated to the original diagnosis and compatible with t-AML were excluded. Statistical analysis was primarily descriptive. Data cut-off was July 26, 2023. Results: A total of 58 cases were identified, including 19 cases referenced in prior publications. Of the 58, 11 cases were excluded from this initial analysis, including: 4 cases of t-AML, 2 cases of T-ALL to AML, and 5 “transition” cases. Collectively, 47 cases of LS (43 “confirmed”; 4 “suspected”), spanning across 3 continents and 8 countries, were analyzed. (Fig. 1A) Cases included transition from B-ALL to AML in 36 (76.6%) and to MPAL/biphenotypic/ambiguous lineage in 11 (23.4%). Two likely had MPAL at diagnosis and a third with chronic myeloid leukemia. The median age at initial diagnosis was 8.4 years (range, 1 day-76.5 years); median age at LS presentation was 11.0 years (range 0.4-77.3 years). Twenty-three (48.9%) were male and 19 (40.4%) had prior stem cell transplant (SCT). Baseline cytogenetics showed KMT2A rearrangement in 27 (57.4%). Baseline myeloid antigen co-expression was seen in 22 of 23 patients with submitted data, but variation in degree of expression across patients and antigens was substantial. The most proximal immunotherapy prior to development of LS was CAR T-cells in 23 (48.9%) and blinatumomab in 24 (51.1%). The median time from the most proximal immunotherapy to development of LS was 1.6 months (range, 7 days-36.5 months). In 7 (29.2%) patients receiving blinatumomab, LS developed during the infusion. LS presented as isolated marrow relapse in 27 (57.4%), isolated CNS in 2 (4.3%), isolated non-CNS extramedullary disease in 3 (6.4%), combined relapse in 14 (29.8%) and unreported in 1. First line treatment for LS was chemotherapy induction in 31 (66.0%), palliative care/no therapy in 8 (17.0%), and alternative therapies in the remaining 8 (17.0%). In 35 (74.5%) patients, remission induction was the goal of first line therapy. Fifteen (31.9%) achieved a complete remission (CR) of whom 2 were treated with palliative intent. Across all patients, 8 (17.0%) are alive in remission, the longest being 4.7 years from LS diagnosis; 2 (4.3%) are alive with active LS and 37 (78.7%) died from LS, their original disease, or complications of treatment of LS (Fig 1B). For those alive in CR (n=8), 7 (87.5%) proceeded to a consolidative SCT for treatment of LS and 1 patient, an octogenarian remains in remission after AML directed therapy. Conclusions: LS is emerging as an important mechanism of immune escape following immunotherapy. Project EVOLVE provides the largest dataset of patients with LS to date. This systematic, international effort reveals substantial complexity and variability in diagnosing and managing LS. Unfortunately, outcomes following LS are grim, underscoring the critical need to identify risk factors of and optimal therapies for this leukemia transformation.
Life Long High Fat Diet Causes Hepatic Lipid Accumulation by Programming Lipid Synthesis Genes in Liver of Male Rat
Moody, Laura, Kriska, Adam, Chen, Hong , Jung, Paul , Zhou, Dan , Pan, Yuan‐Xiang

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.850.11 Get It

Life long high fat (HF) diet has been shown to cause more hepatic lipid accumulation in offspring as compared to a post‐weaning HF diet. However, it is still unclear what the epigenetic mechanisms are. We hypothesize that a life long HF diet will cause greater hepatic lipid accumulation as compared to a post‐weaning HF diet. The objective of this study is to understand the epigenetic mechanisms of hepatic lipid accumulation as an outcome of life long HF diet. Timed‐pregnant Sprague‐Dawley rats were given either a control (C, 16% fat) or HF (HF, 45% fat) diet during gestation and lactation. Pups from both C and HF mothers were weaned onto the same HF diet, creating two offspring groups: C/HF and HF/HF. Rats were sacrificed at 12 weeks of age and the left lobe of the liver was used for further analysis. Liver histology showed greater hepatic fat accumulation in the HF/HF group. Gene expression data was measured for multiple genes in the following pathways: glycolysis, gluconeogenesis, fatty acid synthesis, and triacylglycerol synthesis. Only glycerol‐3‐phosphate acyltransferase (GPAM) and fatty acid synthase (FASN) showed higher levels of mRNA. DNA methylation of specific genes was analyzed based on data obtained from methyl‐DNA immunoprecipitation with high‐throughput sequencing. Differential methylation was observed for both GPAM and FASN. Our data suggests that life long HF diet increases lipid storage by increased hepatic GPAM and FASN gene expression in male rats, potentially through epigenetic regulation.
BIOM-16. LONGITUDINAL GLIOMA CEREBROSPINAL FLUID CELL-FREE DNA FOR MONITORING AND TREATMENT RESPONSE ASSESSMENT
Riviere-Cazaux, Cécile , Dong, Xiaoxi , Mo, Wei , Luo, Shujun , Wang, Amy, Du, Pan , Warrington, Arthur E. , Ghadimi, Keyvan , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v7-v7

10.1093/neuonc/noad179.0027 Get It

Abstract Few methods exist via which to assess treatment response with high fidelity in gliomas. While CSF has previously been used as a source of cfDNA, it remains unknown how cfDNA abundance and sequencing changes throughout treatment and inevitable recurrence in gliomas. We utilized our biobank of longitudinal intracranial CSF specimens to determine the potential utility of CSF cfDNA as a monitoring tool for treatment response in patients with gliomas. Longitudinal CSF specimens were acquired via Ommaya reservoirs (NCT04692337) or ventriculoperitoneal shunts (NCT04692324) in patients with gliomas. cfDNA was extracted from 1-5 mL of CSF, and next-Generation sequencing or low-pass whole genome sequencing (LPWGS) was performed by Predicine, Inc. CSF acquired prior to versus after resection demonstrated an increase in quantified cfDNA (2.97x, range: 1.58-5.26x), consistent with the impact of increased parenchymal disruption and closer contact with CSF. Thereafter, CSF cfDNA continued to decrease throughout chemoradiation and adjuvant treatment and increased at recurrence, including in patients co-enrolled in immunotherapy trials for IL-7 agonists and pembrolizumab. Copy number burden (CNB) increased by the time of recurrence in three patients with known disease progression, and continued to decrease throughout immunotherapy treatment in one patient despite concerns of pseudoprogression. In one patient with a hypermutated glioblastoma, CSF cfDNA revealed over 59 genomic alterations, including MAP2K1, KIT, and PDGFRA, excluding even more variants of unknown significance, each of which had been detected in sequencing of the tissue acquired at resection and subsequently decreased with chemoradiation. In another patient with a known progressing EGFR-amplified GBM, over 200 new variants were identified by the patient’s final sample and EGFR copy number increased from 2 to over 30. In conclusion, cfDNA analysis over a patient’s disease course, including resection and treatment with standard-of-care and experimental therapies, may be of use for disease monitoring and treatment response.
Risk factors for failure of conversion from epidural labor analgesia to cesarean section anesthesia and general anesthesia incidence: an updated meta-analysis
Pan, Li , Ma, Xiaoting , Han, Shuang , Ruetzler, Kurt , Lal, Amos , Cao, Longlu, Duan, Ran , Li, Jianli , Lal, Amos , Li, Pan, Kawagoe, Izumi , Duan, Ran

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | November 5, 2023 | Volume: 36 | Issue: 2 | Pages: No page available

10.1080/14767058.2023.2278020 | PMID 37926901 Get It

S683 Association of Ultra-Processed Food and Unprocessed or Minimally Processed Food Consumption With Bowel Function Among US Adults
Martinez, Euridice , Lee, Jeffrey K. , Zhang, Xuehong , Samadder, N. Jewel , Lo, Chun‐Han , Zhao, Longgang , Pan, Chun‐Wei , Singh, Harminder

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S499-S500

10.14309/01.ajg.0000952372.70705.ed Get It

S238 Comparative Analysis of Clostridioides difficile Infection Outcomes in Patient With Solid Organ Transplant vs Without Solid Organ Transplant in the United States
Vikash, Fnu , Kumar, Vikash , Syed, Noor, Taj, Sobaan , Kilani, Yassine , Malik, Talia F. , Hussain, Sana , Vikash, Sindhu, Patel, Sunny , Ali, Hassam , Pan, Chun‐Wei , Osagiede, Osayande , Miranda, Clive Jude

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S178-S179

10.14309/01.ajg.0000950592.66136.1c Get It

Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate
Zhao, Jinge , Xu, Nanwei , Nie, Ling , Zhang, Mengni , Zheng, Linmao , Cai, Diming , Sun, Xiaomeng , Chen, Junru , Dai, Jindong , Ni, Yuchao , Wang, Zhipeng , Zhang, Xingming , Liang, Jiayu, Chen, Yuntian , Pan, Xiuyi , Yin, Xiaoxue , Liu, Haoyang , Zhao, Fengnian , Zhang, Bei , Chen, Hao , Miao, Jiashun , Qin, Cong , Zhao, Xiaochen , Yao, Jin , Liu, Zhenhua , Liao, Banghua , Wei, Qiang , Shen, Pengfei , Chen, Ni , Zeng, Hao , Sun, Guangxi , Zhu, Sha , Nie, Ling , Zhang, Mengni , Zheng, Linmao , Cai, Diming , Sun, Xiaomeng , Chen, Junru , Dai, Jindong , Ni, Yuchao , Wang, Zhipeng , Zhang, Xingming , Liang, Jiayu , Chen, Yuntian , Hu, Xu , Pan, Xiuyi , Yin, Xiaoxue , Liu, Haoyang , Zhao, Fengnian , Zhang, Bei , Chen, Hao , Miao, Jiashun , Qin, Cong , Zhao, Xiaochen , Yao, Jin , Liu, Zhenhua , Liao, Banghua , Wei, Qiang , Li, Xiang , Liu, Zhenhua , Gao, Allen C , Huang, Rui , Shen, Pengfei , Chen, Ni , Zeng, Hao , Sun, Guangxi , Zhu, Sha , Liu, Jiyan , Huang, Haojie

Mayo Clinic

Cancer Research | October 17, 2023 | Volume: 84 | Issue: 1 | Pages: 154-167

10.1158/0008-5472.can-23-1176 | PMID 37847513 Get It

Abstract Intraductal carcinoma of the prostate (IDC-P) is a lethal prostate cancer subtype that generally coexists with invasive high-grade prostate acinar adenocarcinoma (PAC) but exhibits distinct biological features compared with concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing of IDC-P, concurrent invasive high-grade PAC lesions, and adjacent normal prostate tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns of concurrent IDC-P and PAC were identified: early divergent, late divergent, and clonally distant. In contrast to those with a late divergent evolutionary pattern, tumors with clonally distant and early divergent evolutionary patterns showed higher genomic, epigenomic, transcriptional, and pathologic heterogeneity between IDC-P and PAC. Compared with coexisting PAC, IDC-P displayed increased expression of adverse prognosis–associated genes. Survival analysis based on an independent cohort of 505 patients with metastatic prostate cancer revealed that IDC-P carriers with lower risk International Society of Urological Pathology (ISUP) grade 1–4 adenocarcinoma displayed a castration-resistant free survival as poor as those with the highest risk ISUP grade 5 tumors that lacked concurrent IDC-P. Furthermore, IDC-P exhibited robust cell-cycle progression and androgen receptor activities, characterized by an enrichment of cellular proliferation–associated master regulators and genes involved in intratumoral androgen biosynthesis. Overall, this study provides a molecular groundwork for the aggressive behavior of IDC-P and could help identify potential strategies to improve treatment of IDC-P. Significance: The genomic, transcriptomic, and epigenomic characterization of concurrent intraductal carcinoma and adenocarcinoma of the prostate deepens the biological understanding of this lethal disease and provides a genetic basis for developing targeted therapies.